Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Sept 2021

Zhang N, Gao Y, Zeng Z, Luo Y, Jiang X, Zhang J, Li J, Zhang J, Gong Y, Xie C

Abstract excerpt

BACKGROUND: Poly-(ADP-Ribose)-Polymerase inhibitors (PARPi) were reported as radiosensitizers in non-small cell lung cancer (NSCLC) with wide-type epidermal growth factor receptor (EGFR), but the effects of radiation combined with PARPi were not investigated in EGFR-mutated NSCLC. Moreover, the underlying mechanisms were not well examined. This study aimed to study the efficacy of radiation combined with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemokine CCL5
Share to Chemokine CXCL10

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Immunocompetence

Share to Indazoles

Share to Interferon Regulatory Factor-3

Share to Radiation-Sensitizing Agents

Share to Tumor Stem Cell Assay

Source

Identifiers

PMID: 33774805
DOI: 10.1007/s12094-021-02591-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.PMID 33774805Read ↗

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.Semantic proximity Read ↗

Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathwaySemantic proximity Read ↗

Irradiation suppresses STAT3-mediated MCL1 expression to augment CD8+ T cells cytotoxicity against EGFR-positive lung cancerSemantic proximity Read ↗

PARP-1 genetic polymorphism associated with radiation sensitivity of non-small cell lung cancer.Semantic proximity Read ↗

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cellsSemantic proximity Read ↗

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repairSemantic proximity Read ↗

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancerSemantic proximity Read ↗

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.Semantic proximity Read ↗

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

Thoracic Radiotherapy and Radiation Time Would Affect the Efficacy of Advanced Non-Small Cell Lung Cancer for Patients Who Responded to TKIs Treatment.Semantic proximity Read ↗

PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancerSemantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.